BUSINESS

• BA.4/5-Based Jab Filed for 6 Months to 4 Years in Japan: Pfizer/BioNTech
  April 12, 2023

• Meiji/CSL Seqirus Tie Up for Sales of COVID-19 mRNA Vaccine in Japan
  April 12, 2023

• Shionogi Seeks EUA for Xocova in Taiwan
  April 12, 2023

• Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
  April 12, 2023

• Wakamoto to Halt Shipments of MaQaid on Quality Issues
  April 11, 2023

• Shionogi Begins Global PIIb Stroke Study for Regeneration-Inducing Medicine
  April 11, 2023

• MSD Rolls Out 15-Valent Pneumococcal Vaccine Vaxneuvance in Japan
  April 11, 2023

• Amgen Eyes Simultaneous Filing in Japan, US, EU for 3 Key Drivers, including Next-Gen BiTE Drug: R&D Chief
  April 11, 2023

• Ono/BMS Settles PD-1/PD-L1 Patent Row with Dana-Farber
  April 10, 2023

• Generic Shipment Price Rate Likely Rose 1.5% for FY2023 Revision, Weighing on Wholesalers
  April 10, 2023

• Sanofi Discontinues Sales of Allegra Dry Syrup in Japan
  April 10, 2023

• Insud’s Oral Contraceptive Filed in South Korea: ASKA
  April 10, 2023

• Japan Ethical Drug Sales Up 0.6% in February: Crecon
  April 10, 2023

• Lenvima/Keytruda Combo Fails in 1st-Line Melanoma Study
  April 10, 2023

• JCR, Sumitomo Sign Copromotion Pact for Izcargo in Japan
  April 7, 2023

• Japan Pharma Sales Up 1.3% in FY2022: Encise
  April 7, 2023

• Kissei’s ITP Med Tavalisse Now Available in Japan
  April 7, 2023

• Major Renovation at Eisai’s Tsukuba Lab Completed
  April 7, 2023

• Kowa Kicks Off Another PIII for Ripasudil for Fuchs Endothelial Corneal Dystrophy
  April 7, 2023

• MSD Japan Nets 24% Growth in 2022 on Lagevrio, Keytruda; President Wary of Further Re-Pricing
  April 6, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 140
• 141
• 142
• 143
• 144
• 145
• 146
• 147
• 148
• …
• Next ›
• 最終 »